This article is from: srnnews.com
Feb 27 (Reuters) – Flagship-backed Generate Biomedicines’ shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings.
(Reporting by Pragyan Kalita in Bengaluru; Editing by Sahal Muhammed)
Brought to you by www.srnnews.com
